KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Non-Current Liabilities (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $4.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 10.31% year-over-year to $4.2 billion, compared with a TTM value of $4.2 billion through Dec 2025, up 10.31%, and an annual FY2025 reading of $4.2 billion, up 10.31% over the prior year.
  • Total Non-Current Liabilities was $4.2 billion for Q4 2025 at Alnylam Pharmaceuticals, up from -$9.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $4.2 billion in Q4 2025 and bottomed at -$9.8 million in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $3.2 billion, with a median of $3.5 billion recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities surged 146.4% in 2021, then tumbled 100.26% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $3.0 billion in 2021, then rose by 18.13% to $3.5 billion in 2022, then rose by 7.16% to $3.7 billion in 2023, then grew by 1.01% to $3.8 billion in 2024, then rose by 10.31% to $4.2 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ALNY at $4.2 billion in Q4 2025, -$9.8 million in Q3 2025, and $3.9 billion in Q2 2025.